Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Oxford Biodynamics Raises $12.5 Million from China's GL Capital for Biomarkers

publication date: Aug 24, 2018

Oxford Biodynamics PLC raised $12.5 million from GL Capital Group, a Shanghai private equity investor with a healthcare focus. OBD uses a proprietary platform, EpiSwitch™, to develop biomarkers based on chromosome conformation signatures, which allow early identification of disease-causing changes. GL Capital, which will own a 5% stake in Oxford Biodynamics, will be in charge of finding China partners for OBD's products/services. More details....

Stock Symbol: (LON: OBD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.